{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06325748",
            "orgStudyIdInfo": {
                "id": "SENTI-202-101"
            },
            "organization": {
                "fullName": "Senti Biosciences",
                "class": "INDUSTRY"
            },
            "briefTitle": "SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS",
            "officialTitle": "SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Hematological Malignancies",
            "therapeuticArea": [
                "Other"
            ],
            "study": "senti-off-the-shelf-logic-gated-car-nk-cell-therapy-in-adults-with-and-or-blood-cancers-including-aml-mds"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-22",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2040-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-13",
            "studyFirstSubmitQcDate": "2024-03-19",
            "studyFirstPostDateStruct": {
                "date": "2024-03-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Senti Biosciences",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.",
            "detailedDescription": "This is a dose-finding study of SENTI-202, comprised of an initial dose finding using a modified \"3+3\" study design to determine the maximum tolerated dose (MTD) and recommended phase two dose (RP2D) of SENTI-202 when administered after lymphodepleting chemotherapy (Part 1) followed by disease-specific expansion cohorts at the RP2D (Part 2)."
        },
        "conditionsModule": {
            "conditions": [
                "AML/MDS",
                "CD33 Expressing Hematological Malignancies",
                "FLT3 Expressing Hematological Malignancies"
            ],
            "keywords": [
                "SENTI-202",
                "CAR NK",
                "natural killer cell",
                "CD33",
                "FLT3",
                "allogeneic",
                "logic gate",
                "relapsed/refractory AML",
                "relapsed/refractory MDS",
                "inhibitory CAR",
                "activating CAR",
                "NOT logic gate",
                "IL15",
                "interleukin 15",
                "cell therapy",
                "off-the-shelf",
                "leukemic stem cells",
                "blastic plasmacytoid dendritic cell neoplasm (BPDCN)",
                "multiple myeloma (MM)",
                "mixed phenotype acute leukemia (MPAL)",
                "endomucin"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 21,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "SENTI-202 CAR NK cell therapy",
                    "type": "EXPERIMENTAL",
                    "description": "Part 1 Dose Finding: Sequential cohorts will receive doses of SENTI-202 using a modified 3+3 study design to determine the recommended phase 2 dose (RP2D). The starting dose will be 1 billion cells. Other doses may be explored depending on study data.\n\nPart 2 Cohort Expansion: After determination of the RP2D, additional subjects will be enrolled in disease-specific expansion cohorts at that dose to further explore safety, biodynamics, and anti-cancer activity of SENTI-202",
                    "interventionNames": [
                        "Biological: SENTI-202"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "SENTI-202",
                    "description": "SENTI-202 is an investigational off-the-shelf CAR NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematological malignancies while sparing healthy cells using a NOT logic gate.\n\nSENTI-202 is administered in 3 weekly doses (Days 0, 7, 14) of a 28-day treatment cycle following a lymphodepletion conditioning regimen of fludarabine and cytarabine (flu/Ara-C). Subjects will receive a minimum of 1 and maximum of 3 treatment cycles.",
                    "armGroupLabels": [
                        "SENTI-202 CAR NK cell therapy"
                    ],
                    "otherNames": [
                        "Fludarabine",
                        "Cytarabine (ara-C)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety and tolerability for dose determination of SENTI-202",
                    "description": "Incidence, type, frequency, and severity of adverse events and dose limiting toxicities will be assessed to determine the maximum tolerated dose and/or recommended phase 2 dose",
                    "timeFrame": "At the end of each treatment cycle (each cycle is 28 days) and through study completion, up to 2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Anti-cancer activity of SENTI-202",
                    "description": "The response rate to SENTI-202 will be measured using clinical measures of benefit as defined by standard consensus criteria for the respective disease",
                    "timeFrame": "Through study completion, up to 2 years"
                },
                {
                    "measure": "Pharmacokinetic (PK) and pharmacodynamic (PDn) profile of SENTI-202",
                    "description": "Levels of circulating SENTI-202 and peripheral cytokine levels will be measured to assess the PK/PDn profile of SENTI-202",
                    "timeFrame": "Through study completion, up to 2 years"
                },
                {
                    "measure": "Host immune response to SENTI-202",
                    "description": "Anti-SENTI-202 immune response and RCR will be measured in blood samples",
                    "timeFrame": "Through study completion, up to 2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects with CD33 and/or FLT3 expressing malignancies, including:\n\n  * Relapsed refractory acute myeloid leukemia (AML) with morphologic relapse as defined by \u22655% bone marrow blasts who have received at least 1 prior line, but no more than 3 prior lines of standard anti-AML therapy. Subjects with FLT3-mutated or IDH \u00bd-mutated disease must have received at least one prior targeted therapy.\n  * Relapsed refractory myelodysplastic syndrome (MDS) with increased blasts who have received at least 1 prior line, but no more than 2 prior lines of anti-MDS therapy\n  * Other hematological malignancies who have received at least 1 prior line of standard of care for the respective disease\n  * Documentation of CD33 expression (or FLT3 expression if available) by individual institutional standard of care\n* ECOG performance score of 0-1\n* Adequate organ function including platelet count \\>20x109/L (platelet transfusion is permitted)\n* Adequate recovery from toxicities from previous cancer treatments, as described in the study protocol\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* White blood cell (WBC) count of \u226520\u00d7109/L or circulating blasts \u226510\u00d7109/L or rapidly progressive/hyperproliferative disease\n* Acute promyelocytic leukemia with t(15;17) (q22;q12) or abnormal promyelocytic leukemia/retinoic acid receptor alpha (APML-RARA)\n* MDS with fibrosis (MDS-f) or known prior history of constitutional conditions/syndromes with chemo-responsive AML\n* Evidence of leukemic meningitis or known active central nervous system disease\n* Presence of extra-medullary disease or myeloid sarcoma alone with no morphologic hematologic relapse\n* Prior use of certain anti-cancer therapies and/or use within a certain number of days prior to SENTI-202 study treatment, as described in the study protocol\n* Hematopoietic cell transplantation (HCT) less than 100 days prior to the first dose of SENTI-202\n* Prior NK cell or CAR T cell therapy at any time\n* Prior donor lymphocyte infusion (DLI), except if after HCT for MRD+ disease\n* Medical conditions or medications prohibited by the study protocol\n* Pregnant or breastfeeding female",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "74 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Amy Alford, MA",
                    "role": "CONTACT",
                    "phone": "650-239-2030",
                    "email": "clinicaltrials@sentibio.com"
                },
                {
                    "name": "Rochelle Emery, MD",
                    "role": "CONTACT",
                    "phone": "650-239-2030",
                    "email": "clinicaltrials@sentibio.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Rochelle Emery, MD",
                    "affiliation": "Senti Biosciences, Medical Director",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "UCLA Medical Center",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Bruck Habtemariam",
                            "role": "CONTACT"
                        },
                        {
                            "role": "CONTACT",
                            "phone": "310-794-0242"
                        },
                        {
                            "name": "Gary Schiller, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Colorado Blood Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sarah Cannon Research Institute",
                            "role": "CONTACT",
                            "phone": "844-482-4812"
                        },
                        {
                            "name": "Alireza Eghtedar, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Mayo Clinic",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Jacksonville",
                    "state": "Florida",
                    "zip": "32224",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Hemant Murthy, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Hemant Murthy, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.33218,
                        "lon": -81.65565
                    }
                },
                {
                    "facility": "TriStar Bone Marrow Transplant",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sarah Cannon Research Institute",
                            "role": "CONTACT",
                            "phone": "844-482-4812"
                        },
                        {
                            "name": "Stephen Strickland, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Farhad Ravandi, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Farhad Ravandi, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Methodist Healthcare",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sarah Cannon Research Institute",
                            "role": "CONTACT",
                            "phone": "844-482-4812"
                        },
                        {
                            "name": "Nosha Farhadfar, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "Royal Prince Alfred Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Camperdown",
                    "state": "New South Wales",
                    "zip": "2050",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Edward Abadir",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Edward Abadir, MBBS FRACP FRCPA",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.88965,
                        "lon": 151.17642
                    }
                },
                {
                    "facility": "Peter MacCallum Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Melbourne",
                    "state": "Victoria",
                    "zip": "3000",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Ashish Bajel",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Ashish Bajel, MBBS FRACP FRCPA",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -37.814,
                        "lon": 144.96332
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000019337",
                    "term": "Hematologic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21314",
                    "name": "Hematologic Neoplasms",
                    "asFound": "Hematological Malignancies",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M12058",
                    "name": "Multiple Myeloma",
                    "relevance": "LOW"
                },
                {
                    "id": "M27588",
                    "name": "Neoplasms, Plasma Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3947",
                    "name": "Multiple Myeloma",
                    "relevance": "LOW"
                },
                {
                    "id": "T174",
                    "name": "Acute Leukemia of Ambiguous Lineage",
                    "relevance": "LOW"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "T1792",
                    "name": "Dendritic Cell Tumor",
                    "relevance": "LOW"
                },
                {
                    "id": "T773",
                    "name": "Blastic Plasmacytoid Dendritic Cell",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003561",
                    "term": "Cytarabine"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6766",
                    "name": "Cytarabine",
                    "asFound": "Delivered",
                    "relevance": "HIGH"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}